Prostate Cancer - Results from #240

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends. September 24, 2024

American Radium Society Appropriate Use Criteria for the Workup and Treatment of Local Intraprostatic Recurrence of Prostate Cancer Following Definitive Radiotherapy. September 24, 2024

Virtual reality as an adjunct to traditional patient counseling in patients with newly-diagnosed localized prostate cancer. September 24, 2024

Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series. September 24, 2024

Whole-body MRI for staging prostate cancer: a narrative review. September 24, 2024

Disparities in the Utilization of MRI for Prostate Cancer Detection: A Population-Based Study. September 24, 2024

Comparison of Industry-Sponsored Trials (IST) and Investigator-Initiated Trials (IIT) in Advanced Genitourinary Cancers in the United States, Canada, United Kingdom and France. September 23, 2024

Does sexual rehabilitation work for gay and bisexual prostate cancer patients? Acceptability, feasibility, and efficacy results from the Restore-2 randomized controlled trial. September 23, 2024

Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories. September 23, 2024

Systemic treatments for advanced prostate cancer: relationship between health insurance plan and treatment costs. September 23, 2024

Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction. September 23, 2024

Beyond Medical Bills: The Indirect Costs of Prostate Cancer. September 23, 2024

A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study. September 23, 2024

Stereotactic radiotherapy for localized prostate cancer: 10-year outcomes from three prospective trials. September 20, 2024

Lipid Metabolism Modulatory Cisplatin Prodrug Sensitizes Resistant Prostate Cancer toward Androgen Deprivation Therapy. September 20, 2024

Ipilimumab with Nivolumab in molecular-Selected patients with castration-resistant PRostate cancer: primary analysis of the Phase 2 INSPIRE trial. September 20, 2024

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. September 20, 2024

Secondary Cancer in Prostate Cancer Patients Treated With Advanced External Beam Radiation Therapy. September 20, 2024

A Common Culprit Drives Prostate Cancer Progression September 19, 2024

The polyunsaturated fatty acid docosahexaenoic affects mitochondrial function in prostate cancer cells. September 19, 2024

Page 13 of 1437